146 related articles for article (PubMed ID: 19609538)
1. A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Kim HS; Park MJ; Uhm JE; Lee Y; Lee HY; Kang EM; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS
Int J Colorectal Dis; 2009 Nov; 24(11):1311-6. PubMed ID: 19609538
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
3. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
Shin SJ; Jung M; Jeung HC; Kim HR; Rha SY; Roh JK; Chung HC; Ahn JB
Invest New Drugs; 2012 Aug; 30(4):1501-10. PubMed ID: 21567184
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
Li J; Yin J; Zhu X; Liu Y; Cao J; Lu F; Zuo Y
Anticancer Drugs; 2008 Aug; 19(7):745-8. PubMed ID: 18594218
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.
Kim SY; Hong YS; Kim BC; Park JW; Choi HS; Jeong SY; Kim DY; Hong CW; Sohn DK; Jung KH
Invest New Drugs; 2009 Jun; 27(3):269-74. PubMed ID: 18815728
[TBL] [Abstract][Full Text] [Related]
9. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
Ohue M; Hamaguchi T; Ito Y; Sakai D; Noura S; Kinugasa Y; Fujita S; Shimada Y; Saito N; Moriya Y
Int J Clin Oncol; 2015 Apr; 20(2):338-44. PubMed ID: 24839048
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
13. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Rosati G; Rossi A; Tucci A; Pizza C; Manzione L
Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626
[TBL] [Abstract][Full Text] [Related]
15. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
18. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY; S Hong Y; K Shim E; Kong SY; Shin A; Baek JY; Jung KH
Br J Cancer; 2013 Sep; 109(6):1420-7. PubMed ID: 23963147
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Zeuli M; Di Costanzo E; Sdrobolini A; Gasperoni S; Paoloni FP; Carpi A; Moscetti L; Cherubini R; Cognetti F; ;
Ann Oncol; 2001 Dec; 12(12):1737-41. PubMed ID: 11843252
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
